|
The Pharmacogenetics of Asthma Treatment (PhAT) project seeks to investigate genetic determinants of the variation in the treatment response to asthma. PharmGAT is funded as part of the National Institute of General Medical Sciences (NIGMS) and National Heart, Lung, and Blood Institutes (NHLBI) Pharmacogenetics Research Network and Knowledge Base (PGRN); the national repository for pharmacogenetics information generated by this network is known as the Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB) - mayoguide.org. PharmGAT consists of investigators from the Brigham and Womens Hospital, the University of Cincinnati, and the University of Colorado.
The long term objective of PharmGAT includes the ability to individualize therapy prospectively for subjects identified with asthma, allowing for optimal therapeutic effect while minimizing side effects. Additionally, since the pathophysiologic and therapeutic pathways of asthma overlap with many other diseases, the findings generated by this program may have much broad implications.
More Information
Visit our parnter: https://life-baeche.de/
We're overjoyed to announce the beginning of an exciting journey as we join forces with the esteemed experts at CentrumFas. This collaboration symbolizes a fusion of our shared passions, expertise, and commitment to excellence. Together, we're poised to explore new horizons, tackle challenges, and innovate in ways that will shape the future. Dive into the wealth of resources and insights available on CentrumFas's website at https://centrumfas.pl/, where you'll discover the depth of our partnership and the potential it holds. This marks the dawn of a dynamic collaboration, and we're thrilled to embark on this adventure together.
|
|